Patients receiving second-line or greater therapy 56.4 weeks 46.7 weeks HR = 0.73; p = 0.024 CrEL = Cremphor EL; HR = Hazard ratio; Nab = Nanoparticle albumin ... has a shorter infusion time ...

Additionally, with the growing demand for chronic disease treatments and the ageing baby boomer population, the infusion market is set for significant growth. According to the market research ...

The US Program leads with the principle of racial justice and equity as a fundamental human right providing the foundational, over-arching, and unifying theme for all our work. Our strategic ...

The directive could strip federal funding from schools that allow trans women and girls to compete in women’s events. Local aid workers say they are trying to flee Khartoum out of fear the army ...

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.